Cover Image
市場調查報告書

院內感染 (HAI) :設備、醫藥品,及環保產品

Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products

出版商 BCC Research 商品編碼 210214
出版日期 內容資訊 英文 243 Pages
訂單完成後即時交付
價格
Back to Top
院內感染 (HAI) :設備、醫藥品,及環保產品 Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products
出版日期: 2015年05月21日 內容資訊: 英文 243 Pages
簡介

2014年的全球院內感染 (HAI) 治療規模,約152億美金。該市場預計從2015年到2020年以6.1%的年複合成長率成長,2015年擴大到171億美元,2020年達到230億美元。

本報告提供全球院內感染 (HAI) 趨勢相關調查分析、各種院內感染概要、各地區的趨勢、感染用的醫藥品、環保產品,及設備概要、各國的法律規章、參與企業簡介等彙整資料,為您概述為以下內容。

第1章 簡介

第2章 摘要

第3章 全球HAI概要

  • HAI的風險
  • 最常見的院內感染
  • 革蘭氏陽性菌
  • 革蘭氏陰性菌
  • 病毒感染
  • 真菌感染
  • 酵母菌感染疾病
  • HAI預防
  • 院內感染的發生地點
  • 積極的治療
  • HAI的人力損失和金錢成本
  • 醫療產業的變化
  • 法規

第4章 院內感染用醫藥品市場 (HAI用醫藥品市場)

  • HAI所採用的醫藥品
  • 病毒性HAI醫藥品
  • 病毒性HAI醫藥品市場:各企業
  • 病毒性HAI醫藥品市場:各症狀
  • 細菌性HAI
  • 抗生素抗性的威脅
  • 細菌性HAI醫藥品
  • 藥物類別
  • 全球細菌性醫藥品市場佔有率:各企業
  • 細菌性醫藥品市場:各類型
  • 真菌性HAI醫藥品
  • 真菌性醫藥品市場:各企業
  • 全球機會
  • 全球醫藥品成長率
  • 全球市場的新興各國所扮演的角色

第5章 HAI環境治療市場

  • 全球HAI環境治療市場
  • 空氣傳播感染治療
  • 水感染治療
  • 清洗等級
  • 患者皮膚用產品
  • 各地區分析
  • 南北美洲
  • EMEA (歐洲、中東、非洲)
  • 亞洲

第6章 HAI醫療設備:導管、患者用換氣設備及管線無菌過濾器

  • 抗菌塗料
  • 導管
  • 導管塗料
  • 表面修飾導管
  • 全球導管市場
  • 導尿管
  • 中央靜脈導管
  • 週邊置入型中央靜脈導管 (PICC)
  • 地區市場上導管的成長
  • 患者用換氣設備
  • 換氣設備的種類
  • 患者用換氣市場
  • 氣管內插管、換氣系統
  • in line無菌IV過濾
  • 地區分析
  • 南北美洲
  • EMEA (歐洲、中東、非洲)
  • 亞洲

第7章 目前研究、新的治療方法及市場機會

  • 新興研究
  • 醫藥品治療產品平台
  • 醫藥品研究
    • 真菌感染:開發中的產品
    • 病毒感染:開發中的產品
  • HAI產業的機會/課題
  • 人口統計變化的影響

第8章 專利

  • 專利:各發行日期
  • 專利數:各製造廠商
  • 醫藥品
    • 細菌治療藥的專利
    • 真菌治療藥的專利
    • 病毒治療藥的專利
  • 環境管理
    • 空氣過濾
    • 水過濾
    • 固體廢棄物處理
    • 表面消毒
    • 患者表面消毒的專利
  • 醫療設備
    • 導管
    • 抗菌塗料

第9章 企業名錄

  • 醫藥品
  • 環保產品

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: HLC092C

REPORT HIGHLIGHTS

The global market for selected healthcare-acquired infection (HAI) treatments was valued at nearly $15.2 billion in 2014. This market is expected to increase from nearly $17.1 billion in 2015 to $23 billion by 2020, with a compound annual growth rate (CAGR) of 6.1% from 2015 to 2020.

This report provides:

  • Forecasts of the markets for healthcare-acquired infection (HAI) devices, pharmaceuticals, and therapies by treatment segment and treatment type, including supporting analyses for projections
  • Analyses of global market trends, with data from 2014, estimates for 2015, and projections of CAGRs through 2020
  • Valuable tools for anyone assessing the HAI market and attempting to devise a strategy to successfully compete in the industry
  • Information needed to understand the current market and to address the emerging market.

SCOPE AND FORMAT

This report offers forecasts by treatment segment and type of treatment, from 2015 through 2020, including supporting analyses for projections.

The main market segments are analyzed by pharmaceutical treatments, environmental treatments and infection control devices/products.

This report is a valuable tool for anyone assessing the HAI market and attempting to devise a strategy to successfully compete in this market. This report provides background on the structure of the HAI market and the chief challenges and opportunities it faces. It offers the information needed to understand the current market and to address the emerging one.

The report is an invaluable tool for business planners, acquisition specialists, licensing strategists, product managers, market research analysts, investing consultants and others interested in the HAI market, its products, its participants and its future.

ANALYST'S CREDENTIALS

Peggy S. Lehr is the BCC Research Analyst of this report. Ms. Lehr holds a BS in Journalism from the University of Colorado, Boulder and an MS in Communication from the University of Denver. Ms. Lehr has worked within the publishing industry for both for-profit and not-for-profit organizations, and she specializes in marketing reports on the medical industry. Her latest report, HLC012F-Organ and Tissue Transplantation and Alternatives, was published in March 2015.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • REASONS FOR DOING THE STUDY
  • STUDY GOALS AND OBJECTIVES
  • SCOPE AND FORMAT
  • METHODOLOGIES AND INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • SUMMARY TABLE: GLOBAL MARKET FOR SELECTED HAI TREATMENTS, THROUGH 2020 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL MARKET SHARES OF HAI TREATMENTS BY GEOGRAPHICAL AREA, 2015 AND 2020 (%)

CHAPTER 3 - GLOBAL HAI OVERVIEW

  • RISKS FOR ACQUIRING HAI
  • MOST COMMON HEALTHCARE-ASSOCIATED INFECTIONS
    • TABLE 1: CAUSES AND TYPES OF MOST COMMON HEALTHCARE-ACQUIRED INFECTIONS
  • GRAM-POSITIVE BACTERIA
    • S. AUREUS
      • Transmission Routes
    • MRSA
      • Transmission Routes
    • PNEUMONIA
      • Pseudomonas Aeruginosa
      • Hospital-Acquired Pneumonia (HAP)
      • K. Pneumonia
    • CLOSTRIDIUM DIFFICILE
    • E. COLI
      • UTI Treatment Options
    • GASTROENTERITIS-CAUSING BACTERIA
      • Treatment Options
    • VANCOMYCIN-RESISTANT ENTEROCOCCI (VRE)
      • Types of VRE
    • LEGIONELLA BACTERIA
      • Treatment Options
  • GRAM-NEGATIVE BACTERIA
    • PSEUDOMONAS AERUGINOSA
    • ACINETOBACTER BAUMANNII
    • CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE)
  • VIRAL INFECTIONS
    • HEPATITIS C
      • Scope of Infection
      • Treatment
    • NOROVIRUS
    • INFLUENZA VIRUS
      • Influenza Virus A, B, C
      • Transmission
      • Symptoms
      • Treatment
  • FUNGAL INFECTIONS
    • MEDICAL NEED FOR ANTIFUNGALS
    • ASPERGILLUS INFECTIONS
      • Treatment
  • YEAST INFECTIONS
    • CANDIDA INFECTIONS
  • PREVENTING HAI
    • DETERMINING THE MODE OF TRANSMISSION
    • ROLES OF HEALTHCARE INSTITUTIONS AND INFECTION CONTROL INDIVIDUALS
      • TABLE 2: SELECTED RESPONSIBILITIES OF INFECTION CONTROL TEAM MEMBERS
    • COMPONENTS OF A HAI SURVEILLANCE SYSTEM
      • TABLE 3: MAIN STEPS AND COMPONENTS IN DEVELOPING AN EFFECTIVE INFECTION CONTROL SURVEILLANCE SYSTEM
  • HEALTHCARE INFECTION POINTS OF GENERATION
    • HOSPITAL
      • FIGURE 1: OCCURRENCE OF HAI IN U.S. HOSPITALS BY TYPE, 2011 (%)
      • Hospital Surgical Procedures
    • AMBULATORY SURGERY CENTERS IN THE U.S.
      • Infection Control in ASCs
    • DIALYSIS CENTERS
      • Transmission of VRE in Dialysis Centers
      • Hepatitis Transmission in Dialysis Centers
    • ASSISTED LIVING/LONG-TERM CARE FACILITIES
  • PROACTIVE TREATMENTS
    • THE IMPORTANCE OF HAND WASHING
    • CDC RECOMMENDATIONS FOR PREVENTION
      • TABLE 4: CDC MEASURES FOR PREVENTION OF HEALTHCARE-ACQUIRED INFECTIONS
      • TABLE 5: PERCENTAGE DECREASE IN HAI IN U.S. HOSPITAL SETTINGS, 2008-2013 (%)
    • ENVIRONMENTAL CONTROLS
    • DEVICE DESIGN
  • HUMAN AND MONETARY COSTS OF HAI
    • U.S. HEALTHCARE SPENDING
    • U.S. HEALTHCARE SPENDING ON HAI
      • TABLE 6: ESTIMATED COSTS OF HAI IN U.S. HOSPITALS, 2012 (PER PATIENT OCCURRENCE) ($)
    • EMRA
    • JAPAN
    • RATE OF INFECTION
    • CHINESE MARKET
  • CHANGES IN THE HEALTHCARE INDUSTRY
    • TABLE 7: SELECTED MERGERS AND/OR ACQUISITIONS, 2010-2015 ($ MILLIONS)
  • REGULATIONS
    • AMERICAS
      • Creating Drug Treatments
        • TABLE 8: PROCESS OF CREATING DRUG TREATMENTS IN THE U.S.
      • Infection Control Measures/Protocols
    • U.S. REGULATIONS
      • Hospital Infections Disclosure Act (HIDA)
      • Current and Pending Requirements
        • Affordable Care Act and Implications for the Pharmaceutical Industry
        • Biosimilars
        • CMS Reimbursement for HAI
        • "Never Events" Reimbursement
        • Generating Antibiotics Incentives Now Act (2012)
    • BRAZILIAN REGULATIONS
    • EUROPEAN REGULATIONS
      • Innovative Medicines Initiative (IMI)
      • Implications for Pharmaceutical Manufacturers
    • JAPANESE REGULATIONS
    • CHINESE REGULATIONS

CHAPTER 4 - HAI PHARMACEUTICAL MARKET

  • TABLE 9: BACTERIA THAT COMMONLY CAUSE HAI
  • PHARMACEUTICALS USED FOR HAI
    • TABLE 10: GLOBAL MARKET FOR HAI PHARMACEUTICALS BY TYPE, THROUGH 2020 ($ MILLIONS)
  • VIRAL HAI PHARMACEUTICALS
    • TABLE 11: SELECTED VIRAL HAI PHARMACEUTICALS BY NAME, INDICATION AND MANUFACTURER, 2014
  • VIRAL PHARMACEUTICAL MARKET BY COMPANY
    • FIGURE 2: GLOBAL MARKET SHARES OF HEPATITIS, INFLUENZA AND PNEUMONIA PHARMACEUTICALS TO TREAT HAI BY COMPANY, 2014 (%)
  • VIRAL PHARMACEUTICAL MARKET BY CONDITION
    • TABLE 12: GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT VIRAL HAI BY CONDITION, THROUGH 2020 ($ MILLIONS)
    • FIGURE 3: GLOBAL MARKET SHARE FOR HAI VIRAL PHARMACEUTICALS, BY DISEASE TYPE, 2014 (%)
  • BACTERIAL HAI
  • THE THREAT OF ANTIBIOTIC RESISTANCE
    • THE MICROBIOLOGY OF BACTERIAL RESISTANCE
    • MECHANISMS OF RESISTANCE
      • TABLE 13: ANTIBIOTIC CLASSES AND THEIR MODE OF ACTION
    • METHODS OF RESISTANCE
      • Beta-Lactamase Production
      • Importing Resistance from Other Organisms
      • Alteration of Binding Sites to Circumvent Anti-infective Effectiveness
      • Antibiotic Discharge
    • PRIMARY REASONS FOR ANTIBIOTIC RESISTANCE
      • Incomplete Course of Prescribed Medicine
      • Overuse of Broad-Spectrum Antibiotics
      • Antibiotics and Food Production Animals
        • TABLE 14: ANTIBIOTICS APPROVED FOR USE IN FOOD-PRODUCING ANIMALS BY DRUG CLASS, POUNDS USED, AND PERCENTAGE OF TOTAL, 2009 (POUNDS/%)
      • Patient Pressure
    • RESISTANCE BY CLASS OF ANTIBIOTIC
      • TABLE 15: ANTIBIOTIC RESISTANT ORGANISMS AND DRUG CLASSES AFFECTED
  • BACTERIAL HAI PHARMACEUTICALS
    • TABLE 16: SELECTED BACTERIAL HAI PHARMACEUTICALS BY NAME, INDICATION AND MANUFACTURER, 2014
  • CLASSES OF DRUGS
    • Aminoglycosides
    • B-lactam Antibiotics
      • Cephalosporins
      • Glycopeptides
      • Lincosamides
      • Lipopeptides
      • Carbapenems
    • Penicillins
    • Polypeptides
    • Macrolides
    • Quinolones
    • Tetracyclines
    • Sulfonamides
    • Other Formulations
  • GLOBAL MARKET SHARE FOR BACTERIAL PHARMACEUTICALS BY COMPANY
    • FIGURE 4: GLOBAL MARKET SHARES OF HAI BACTERIAL PHARMACEUTICALS BY COMPANY, 2014 (%)
  • BACTERIAL PHARMACEUTICAL MARKET BY TYPE
    • TABLE 17: GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT BACTERIAL HAI, THROUGH 2020 ($ MILLIONS)
  • FUNGAL HAI PHARMACEUTICALS
    • TABLE 18: SELECT LISTING OF PHARMACEUTICALS TO TREAT FUNGAL INFECTIONS BY NAME, TYPE AND MANUFACTURER, 2014
    • TABLE 19: GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT FUNGAL HAI, THROUGH 2020 ($ MILLIONS)
  • FUNGAL PHARMACEUTICAL MARKET BY COMPANY
    • FIGURE 5: GLOBAL MARKET SHARES OF PHARMACEUTICALS TO TREAT FUNGAL HAI, BY COMPANY, 2014 (%)
  • GLOBAL OPPORTUNITIES
  • GLOBAL GROWTH RATES FOR PHARMACEUTICALS
  • ROLE OF EMERGING COUNTRIES IN GLOBAL MARKETS
    • PHARMACEUTICAL SALES IN EMERGING NATIONS
  • REGIONAL ANALYSIS
    • GLOBAL MARKET FOR HAI PHARMACEUTICALS
      • TABLE 20: GLOBAL MARKET FOR HAI PHARMACEUTICALS BY REGION, THROUGH 2020 ($ MILLIONS)
    • AMERICAS
      • TABLE 21: AMERICAS MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HAI BY REGION, THROUGH 2020 ($ MILLIONS)
      • TABLE 22: AMERICAS MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HAI BY TYPE, THROUGH 2020 ($ MILLIONS)
      • FIGURE 6: AMERICAS HAI PHARMACEUTICAL MARKET SHARES, BY DISEASE TYPE, 2015 AND 2020 (%)
    • EMRA
      • TABLE 23: EMRA MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HAI BY REGION, THROUGH 2020 ($ MILLIONS)
      • TABLE 24: EMRA MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HAI, BY TYPE, THROUGH 2020 ($ MILLIONS)
      • FIGURE 7: EMRA HAI PHARMACEUTICAL MARKET SHARES BY DISEASE TYPE, 2015 AND 2020 (%)
    • ASIA
      • Japan
        • Hepatitis in Japan
      • China
        • Hepatitis in China
        • Surgical Site Infections in China
      • India
      • Australia
        • TABLE 25: ASIAN MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HAI BY REGION, THROUGH 2020 ($ MILLIONS)
        • TABLE 26: ASIAN MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HAI, BY TYPE, THROUGH 2020 ($ MILLIONS)
        • FIGURE 8: ASIAN HAI PHARMACEUTICAL MARKET SHARES BY DISEASE TYPE, 2015 AND 2020 (%)

CHAPTER 5 - HAI ENVIRONMENTAL TREATMENT MARKET

  • GLOBAL HAI ENVIRONMENTAL TREATMENT MARKET
    • TABLE 27: GLOBAL MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS BY TYPE, THROUGH 2020 ($ MILLIONS)
  • AIR TREATMENT
    • ROOM FILTRATION SYSTEMS
    • ROOM PRESSURIZATION
    • HYDROGEN PEROXIDE VAPOR (HPV)
    • ULTRAVIOLET (UV) LIGHT DISINFECTION
  • WATER TREATMENT
    • DESIGN OF SINKS AND OTHER WATER FACILITIES
  • LEVELS OF CLEANING
    • ENVIRONMENTAL CLEANING
      • TABLE 28: SURVIVAL OF HOSPITAL PATHOGENS ON DRY HOSPITAL SURFACES
    • DISINFECTION
      • Levels of Disinfection
      • Disinfectant Drying Time
        • TABLE 29: ADVANTAGES/DISADVANTAGES OF COMMONLY USED DISINFECTANTS
      • Cleaning Monitoring
      • Disinfectants
        • Phenolics
        • Oxidizing Agents
        • Halogens
        • Aldehydes
        • Ortho-phthalaldehyde (OPA)
        • Quaternary Ammonium Compounds
        • Bleach
        • Alcohols
          • TABLE 30: GLOBAL MARKET FOR DISINFECTANT PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2020 ($ MILLIONS)
      • Antimicrobial Copper Surface Coatings
  • PATIENT SKIN PREPARATION
    • POVIDONE-IODINE SOLUTIONS
    • CHLOROHEXIDINE GLUCONATE
      • TABLE 31: GLOBAL MARKET FOR PATIENT SKIN PREPARATION DISINFECTANTS, THROUGH 2020 ($ MILLIONS)
    • STERILIZATION SYSTEMS FOR INFECTION CONTROL
      • TABLE 32: GLOBAL MARKET FOR MEDICAL STERILIZATION PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2020 ($ MILLIONS)
    • FILTRATION
      • TABLE 33: GLOBAL MARKET OF IN-LINE MEDICAL FILTERS USED IN CONJUNCTION WITH MEDICAL ADMINISTRATION OF SOLUTIONS, THROUGH 2020 ($ MILLIONS)
    • CHEMICAL STERILIZATION
      • TABLE 34: GLOBAL MARKET FOR MEDICAL CHEMICAL STERILIZATION EQUIPMENT AND CONSUMABLES, THROUGH 2020 ($ MILLIONS)
      • EtO Sterilization
      • Other Types of Chemical Sterilization
        • Hydrogen Peroxide
        • Ozone
        • Chlorine Dioxide
      • Major Manufacturers in Chemical Sterilization
    • STEAM STERILIZATION
      • TABLE 35: GLOBAL MARKET FOR MEDICAL STEAM STERILIZATION EQUIPMENT AND CONSUMABLES, THROUGH 2020 ($ MILLIONS)
      • TABLE 36: SELECTED MATERIALS THAT RESPOND WELL TO STEAM STERILIZATION
      • Autoclaving
      • Major Players in Heat Sterilization
    • RADIATION STERILIZATION
      • TABLE 37: GLOBAL MARKET FOR RADIATION STERILIZATION PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS BY TYPE, THROUGH 2020 ($ MILLIONS)
      • Gamma Radiation
        • Medical Uses
          • TABLE 38: MICROBES INACTIVATED BY GAMMA IRRADIATION AND THE AMOUNT OF NECESSARY KGY
          • TABLE 39: MEDICAL GRADE POLYMERS CAPABLE OF TOLERATING GAMMA RADIATION (KGY)
    • Electron-Beam Radiation
  • REGIONAL ANALYSIS
    • TABLE 40: GLOBAL MARKET FOR ENVIRONMENTAL PRODUCTS/ EQUIPMENT TO CONTROL HAI, BY REGION, THROUGH 2020 ($ MILLIONS)
  • AMERICAS
    • TABLE 41: AMERICAS MARKET FOR ENVIRONMENTAL PRODUCTS/ EQUIPMENT TO CONTROL HAI BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 42: AMERICAS MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS BY PRODUCT TYPE, THROUGH 2020 ($ MILLIONS)
  • EMRA
    • Patient Skin Preparation Solutions
    • EMRA Market for Environmental Products/Equipment
      • TABLE 43: EMRA MARKET FOR ENVIRONMENTAL PRODUCTS/ EQUIPMENT TO CONTROL HAI BY REGION, THROUGH 2020 ($ MILLIONS)
      • TABLE 44: EMRA MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2020 ($ MILLIONS)
  • ASIA
    • TABLE 45: ASIAN MARKET FOR ENVIRONMENTAL PRODUCTS/ EQUIPMENT TO CONTROL HAI, THROUGH 2020 ($ MILLIONS)
    • TABLE 46: ASIAN MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2020 ($ MILLIONS)

CHAPTER 6 - HAI MEDICAL DEVICES: CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILIZATION FILTERS

  • TABLE 47: GLOBAL MARKET FOR MEDICAL DEVICES THAT ARE DESIGNED TO MINIMIZE HAI, THROUGH 2020 ($ MILLIONS)
  • ANTIMICROBIAL COATINGS
  • CATHETERS
    • FIGURE 9: MAJOR NOSOCOMIAL INFECTIONS IN U.S. ICU BY TYPE AND PERCENT (%)
  • CATHETER COATINGS
    • Common Antimicrobial Coatings
      • Nitrofurazone
      • Minocycline/Rifampin
      • Silver Coating
      • Combination Minocycline-Rifampin-Chlorhexidine Catheters
  • SURFACE-MODIFIED CATHETER
  • GLOBAL HAI CATHETER MARKET
    • TABLE 48: GLOBAL MARKET FOR CATHETERS WITH ANTIMICROBIAL PROPERTIES BY TYPE, THROUGH 2020 ($ MILLIONS)
    • FIGURE 10: PROJECTED HAI CATHETER MARKET SHARES BY TYPE, 2015 AND 2020 (%)
  • URINARY TRACT CATHETERS
  • CENTRAL VENOUS CATHETERS
    • Dialysis Catheters
    • Catheter-Related Bloodstream Infections (CRBSI)
  • PERIPHERALLY INSERTED CENTRAL VENOUS CATHETERS (PICC)
  • MARKET OPPORTUNITIES FOR CATHETER MANUFACTURERS
    • TABLE 49: KEY MANUFACTURERS OF ANTIBIOTIC-COATED CATHETERS BY NAME, LOCATION AND PRODUCTS, 2014
  • CATHETER GROWTH IN REGIONAL MARKETS
    • TABLE 50: GLOBAL HAI CATHETER MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
    • FIGURE 11: PROJECTED GLOBAL HAI CATHETER MARKET SHARES BY REGION, 2015 AND 2020 (%)
  • PATIENT VENTILATION DEVICES
    • TABLE 51: GLOBAL MARKET FOR PATIENT VENTILATION PRODUCTS, THROUGH 2020 ($ MILLIONS)
  • TYPES OF VENTILATION DEVICES
    • Noninvasive Ventilators
  • PATIENT VENTILATION MARKET
    • TABLE 52: GLOBAL MARKET FOR NONINVASIVE VENTILATION SYSTEMS FOR USE WITH HAI-INFECTED PATIENTS, THROUGH 2020 ($ MILLIONS)
  • ENDOTRACHEAL TUBES AND VENTILATION SYSTEMS
    • Coated Endotracheal Tubes
    • Tapered Endotracheal Tubes
      • TABLE 53: GLOBAL MARKET FOR COATED ENDOTRACHEAL TUBES DESIGNED TO MINIMIZE VAP, THROUGH 2020 ($ MILLIONS)
  • IN-LINE STERILE IV FILTRATION
    • TABLE 54: GLOBAL STERILE IV FILTER MARKET, THROUGH 2020 ($ MILLIONS)
  • REGIONAL ANALYSIS
    • TABLE 55: GLOBAL MARKET FOR PATIENT INFECTION CONTROL DEVICES BY REGION, THROUGH 2020 ($ MILLIONS)
    • FIGURE 12: GLOBAL HAI PATIENT INFECTION CONTROL DEVICES MARKET SHARES BY REGION, 2015 AND 2020 (%)
  • THE AMERICAS
    • TABLE 56: AMERICAS MARKET FOR INFECTION CONTROL DEVICES DESIGNED TO MINIMIZE HAI, BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 57: AMERICAS MARKET FOR CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2020 ($ MILLIONS)
  • EMRA
    • TABLE 58: EMRA MARKET FOR INFECTION CONTROL DEVICES DESIGNED TO MINIMIZE HAI, BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 59: EMRA MARKET FOR CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2020 ($ MILLIONS)
  • ASIA
    • TABLE 60: ASIAN MARKET FOR INFECTION CONTROL DEVICES DESIGNED TO MINIMIZE HAI BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 61: ASIAN MARKET FOR CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2020 ($ MILLIONS)

CHAPTER 7 - CURRENT RESEARCH, EMERGING THERAPIES AND MARKET OPPORTUNITIES

  • EMERGING RESEARCH
    • ANTIBACTERIAL SURFACES
    • FIM-D
    • BROAD SPECTRUM ANTIVIRAL
    • "NANOTRAPS"
    • FECAL PILLS TO TREAT C. DIFFICILE
  • PHARMACEUTICAL TREATMENT PRODUCT PIPELINE
    • TABLE 62: HAI PHARMACEUTICAL PRODUCT PIPELINE
    • FIGURE 13: MARKET SHARE BY TYPE OF PHARMACEUTICAL COMPOUND IN DEVELOPMENT, 2014 (%)
  • PHARMACEUTICAL RESEARCH
    • BACTERIAL INFECTIONS: PRODUCTS IN DEVELOPMENT
      • Achaogen
      • Melinata Therapeutics
      • GlaxoSmithKline (GSK)
      • Polyphor
      • The Medicines Company
      • Basilea Pharmaceuticals
      • Cempra Pharmaceuticals
      • Nabriva Therapeutics
      • Furiex Pharmaceuticals
      • Merck
      • Toyama Chemical
      • Crestone Pharma
      • Theravance Biopharma
      • Paratek Pharmaceuticals
      • AstraZeneca
      • Daiichi Sankyo
      • Roche
    • VIRAL INFECTIONS: PRODUCTS IN DEVELOPMENT
      • BioCryst Pharmaceuticals
      • Boehringer Ingelheim
      • Roche
      • Merck
      • Toyama Chemical
      • Gilead Sciences
      • Vertex
      • Bristol-Myers Squibb
  • OPPORTUNITIES/CHALLENGES FOR HAI INDUSTRY
    • CHALLENGES
    • PHARMACEUTICAL MARKET OPPORTUNITIES/CHALLENGES
      • Patent Expiry
        • TABLE 63: SELECTED HAI-RELATED PHARMACEUTICAL PATENT EXPIRATIONS, 2004-2024
      • Pipeline Limitations
      • Regulatory Restrictions
      • Generic Competition
  • THE IMPACT OF DEMOGRAPHIC CHANGES
    • DEMOGRAPHIC CHANGES IN THE U.S.
    • DEMOGRAPHIC CHANGES OUTSIDE THE U.S.

CHAPTER 8 - PATENTS

  • TABLE 64: NUMBER OF SELECTED PATENTS BY TYPE, JANUARY 2010 THROUGH FEBRUARY 2015
  • PATENTS BY DATE OF ISSUE
    • TABLE 65: PHARMACEUTICAL PATENTS BY DATE OF ISSUE, JANUARY 2010 THROUGH MARCH 2015
    • TABLE 66: ENVIRONMENTAL PATENTS* BY DATE OF ISSUE, JANUARY 2010 THROUGH MARCH 2015
    • TABLE 67: MEDICAL DEVICE PATENTS BY DATE OF ISSUE, JANUARY 2010 THROUGH MARCH 2015
  • NUMBER OF PATENTS BY MANUFACTURER
    • TABLE 68: NUMBER OF PATENTS BY MANUFACTURER, JANUARY 2010 THROUGH FEBRUARY 2015
  • PHARMACEUTICALS
    • BACTERIAL PHARMACEUTICAL PATENTS
      • TABLE 69: PATENTS ON BACTERIAL PHARMACEUTICALS, SEPTEMBER 2010 THROUGH MARCH 2015
    • FUNGAL PHARMACEUTICAL PATENTS
      • TABLE 70: PATENTS ON FUNGAL PHARMACEUTICALS, SEPTEMBER 2010 THROUGH FEBRUARY 2015
    • VIRAL PHARMACEUTICAL PATENTS
      • TABLE 71: PATENTS ON VIRAL PHARMACEUTICALS, JANUARY 2011 THROUGH MARCH 2015
  • ENVIRONMENTAL CONTROLS
    • AIR FILTRATION
      • TABLE 72: PATENTS ON AIR FILTRATION, FEB 2011-MARCH 2013
    • WATER FILTRATION
      • TABLE 73: PATENTS ON WATER TREATMENT, SEPTEMBER 2010 TO MARCH 2014
    • SOLID WASTE TREATMENT
      • TABLE 74: PATENTS ON SOLID WASTE TREATMENT, APRIL 2011 THROUGH DECEMBER 2014
    • SURFACE DISINFECTANTS
      • TABLE 75: PATENTS ON SURFACE DISINFECTANTS, JANUARY 2010 TO DECEMBER 2014
    • PATENTS FOR PATIENT DISINFECTION
      • TABLE 76: PATENTS ON PATIENT DISINFECTANTS, DECEMBER 2010 TO APRIL 2013
  • MEDICAL DEVICES
    • CATHETERS
      • TABLE 77: PATENTS ON CATHETERS, JULY 2010 TO FEBRUARY 2015
    • ANTIMICROBIAL COATINGS
      • TABLE 78: PATENTS ON ANTIMICROBIAL COATINGS, AUGUST 2010 THROUGH JANUARY 2015

CHAPTER 9 - COMPANY DIRECTORY

  • PHARMACEUTICALS
    • ABBOTT LABORATORIES
      • Business Overview
      • Products
        • TABLE 79: ABBOTT HAI PRODUCTS
    • ABBVIE INC.
      • Business overview
      • Products
        • TABLE 80: ABBVIE HAI PRODUCTS
    • ACHAOGEN INC.
      • Business Overview
    • ACTAVIS PLC
      • Business Overview
      • Products
        • TABLE 81: ACTAVIS HAI PRODUCTS
    • ASTELLAS PHARMA INC.
      • Business Overview
      • Products
        • TABLE 82: ASTELLAS HAI PRODUCTS
    • ASTRAZENECA PLC
      • Business Overview
      • Products
        • TABLE 83: ASTRAZENECA HAI PRODUCTS
    • B. BRAUN MELSUNGEN
      • Business Overview
      • Products
        • TABLE 84: B. BRAUN HAI PRODUCTS
    • BACTIGUARD AB
      • Business Overview
      • Products
    • BASILEA PHARMACEUTICA LTD.
      • Business Overview
      • Products
        • TABLE 85: BASILEA HAI PRODUCTS
    • BAXTER INTERNATIONAL
      • Business Overview
    • BAYER AG (MILES-BAYER)
      • Business Overview
      • Products
        • TABLE 86: BAYER HAI PRODUCTS
    • BRISTOL-MYERS SQUIBB
      • Business Overview
      • Products
        • TABLE 87: BRISTOL MYERS SQUIBB HAI PRODUCTS
    • GILEAD SCIENCES
      • Business Overview
      • Products
        • TABLE 88: GILEAD SCIENCES HAI PRODUCTS
    • GLAXOSMITHKLINE
      • Business Overview
      • Products
        • TABLE 89: GLAXOSMITHKLINE HAI PRODUCTS
    • JANSSEN THERAPEUTICS (FORMERLY TIBOTEC THERAPEUTICS)
      • Business Overview
      • Products
        • TABLE 90: JANSSEN THERAPEUTICS HAI PRODUCTS
    • JOHNSON & JOHNSON
      • Business Overview
      • Products
        • TABLE 91: JOHNSON & JOHNSON HAI PRODUCTS
    • MELINTA THERAPEUTICS (FORMERLY RIB-X PHARMACEUTICALS)
      • Business Overview
    • MERCK
      • Business Overview
      • Products
        • TABLE 92: MERCK HAI PRODUCTS
    • NOVARTIS PHARMACEUTICALS
      • Business Overview
      • Products
        • TABLE 93: NOVARTIS HAI PRODUCTS
    • PARATEK PHARMACEUTICALS
      • Business Overview
    • PFIZER
      • Business Overview
      • Products
        • TABLE 94: PFIZER HAI PRODUCTS
    • ROCHE PHARMACEUTICALS
      • Business Overview
      • Products
        • TABLE 95: ROCHE HAI PHARMACEUTICAL PRODUCTS
    • SHIRE PLC
      • Business Overview
      • Products
        • TABLE 96: SHIRE HAI PHARMACEUTICAL PRODUCTS
    • SUN PHARMA
      • Business Overview
      • Products
        • TABLE 97: SUN PHARMA HAI PHARMACEUTICAL PRODUCTS
    • TETRAPHASE PHARMACEUTICALS
      • Business Overview
    • THE MEDICINE COMPANY
      • Business Overview
      • Products
        • TABLE 98: THE MEDICINE COMPANY HAI PHARMACEUTICAL PRODUCTS
    • THERAVANCE BIOPHARMA
      • Business Overview
      • Products
        • TABLE 99: THERAVANCE HAI PRODUCTS
    • TOYAMA CHEMICAL CO. LTD.
      • Business Overview
      • Products
        • TABLE 100: TOYAMA CHEMICAL HAI PRODUCTS
    • VENUS REMEDIES LTD.
      • Business Overview
      • Products
        • TABLE 101: VENUS REMEDIES HAI PRODUCTS
  • ENVIRONMENTAL PRODUCTS
    • 3M HEALTHCARE, MEDICAL DIVISION
      • Business Overview
      • Products
    • ADVANCED STERILIZATION PRODUCTS
      • Business Overview
      • Products
    • ANDERSEN PRODUCTS INC.
      • Business Overview
      • Products
    • BELIMED
      • Business Overview
      • Products
    • BETA STAR LIFE SCIENCE EQUIPMENT (R-V INDUSTRIES)
      • Business Overview
      • Products
    • BIOQUELL UK LTD.
      • Business Overview
      • Products
    • CONSOLIDATED STERILIZER SYSTEMS
      • Business Overview
      • Products
    • E-BEAM SERVICES INC.
      • Business Overview
      • Products
    • ECOLAB
      • Business Overview
      • Products
    • EOS SURFACES LLC
      • Business Overview
      • Product
    • GETINGE USA INC.
      • Business Overview
      • Products
    • IBA GROUP
      • Business Overview
      • Products
    • LTE SCIENTIFIC LTD.
      • Business Overview
      • Products
    • LUMALIER
      • Business Overview
    • Products
    • MESA LABORATORIES
      • Business Overview
      • Products
    • METREX RESEARCH
      • Business Overview
      • Products
    • NORION INC. (SEE STERIGENICS)
    • PRIMUS STERILIZER CO. INC.
      • Business Overview
      • Products
    • RUHOF CORP.
      • Business Overview
      • Products
    • SANOSIL INTERNATIONAL
      • Business Overview
      • Products
    • SEALED AIR CORP. (DIVERSEY CARE)
      • Business Overview
      • Products
    • STERIGENICS INTERNATIONAL INC.
      • Business Overview
      • Products
    • STERIS CORP.
      • Business Overview
      • Products
    • SYNERGY HEALTH STERILISATION UK LTD
      • Business Overview
      • Products
    • TERRAGENE SRL
      • Business Overview
      • Products
    • TSO3
      • Business Overview
      • Products
    • TUTTNAUER USA CO. LTD.
      • Business Overview
      • Products
    • ULTRAVIOLET DEVICES INC.
      • Business Overview
      • Products
    • XENEX DISINFECTION SERVICES
      • Business Overview
      • Products
    • INFECTION CONTROL PRODUCTS/DEVICES
    • B BRAUN MELSUNGEN AG
      • Business Overview
      • Products
    • BECTON DICKINSON
      • Business Overview
      • Products
    • CANTEL MEDICAL CORP.
      • Business Overview
      • Products
    • CAREFUSION CORP.
      • Business Overview
      • Products
    • CLOROX CO.
      • Business Overview
      • Products
    • COLOPLAST GROUP
      • Business Overview
      • Products
    • COOK MEDICAL
      • Business Overview
      • Products
    • COVIDIEN PLC (MEDTRONIC)
      • Business Overview
      • Products
    • C.R. BARD
      • Business Overview
      • Products
    • HALYARD HEALTH
      • Business Overview
      • Products
    • ONDINE BIOMEDICAL INC.
      • Business Overview
      • Products
    • ROCHESTER MEDICAL LTD.
      • Business Overview
      • Products
    • SCHULKE & MAYR GMBH
      • Business Overview
      • Products
    • TELEFLEX MEDICAL
      • Business Overview
      • Products
    • WELCH ALLYN INC.
      • Business Overview
      • Products

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL MARKET FOR SELECTED HAI TREATMENTS, THROUGH 2020 ($ MILLIONS)
    • TABLE 1: CAUSES AND TYPES OF MOST COMMON HEALTHCARE-ACQUIRED INFECTIONS
    • TABLE 2: SELECTED RESPONSIBILITIES OF INFECTION CONTROL TEAM MEMBERS
    • TABLE 3: MAIN STEPS AND COMPONENTS IN DEVELOPING AN EFFECTIVE INFECTION CONTROL SURVEILLANCE SYSTEM
    • TABLE 4: CDC MEASURES FOR PREVENTION OF HEALTHCARE-ACQUIRED INFECTIONS
    • TABLE 5: PERCENTAGE DECREASE IN HAI IN U.S. HOSPITAL SETTINGS, 2008-2013 (%)
    • TABLE 6: ESTIMATED COSTS OF HAI IN U.S. HOSPITALS, 2012 (PER PATIENT OCCURRENCE) ($)
    • TABLE 7: SELECTED MERGERS AND/OR ACQUISITIONS, 2010-2015 ($ MILLIONS)
    • TABLE 8: PROCESS OF CREATING DRUG TREATMENTS IN THE U.S.
    • TABLE 9: BACTERIA THAT COMMONLY CAUSE HAI
    • TABLE 10: GLOBAL MARKET FOR HAI PHARMACEUTICALS BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 11: SELECTED VIRAL HAI PHARMACEUTICALS BY NAME, INDICATION AND MANUFACTURER, 2014
    • TABLE 12: GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT VIRAL HAI BY CONDITION, THROUGH 2020 ($ MILLIONS)
    • TABLE 13: ANTIBIOTIC CLASSES AND THEIR MODE OF ACTION
    • TABLE 14: ANTIBIOTICS APPROVED FOR USE IN FOOD-PRODUCING ANIMALS BY DRUG CLASS, POUNDS USED, AND PERCENTAGE OF TOTAL, 2009 (POUNDS/%)
    • TABLE 15: ANTIBIOTIC RESISTANT ORGANISMS AND DRUG CLASSES AFFECTED
    • TABLE 16: SELECTED BACTERIAL HAI PHARMACEUTICALS BY NAME, INDICATION AND MANUFACTURER, 2014
    • TABLE 17: GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT BACTERIAL HAI, THROUGH 2020 ($ MILLIONS)
    • TABLE 18: SELECT LISTING OF PHARMACEUTICALS TO TREAT FUNGAL INFECTIONS BY NAME, TYPE AND MANUFACTURER, 2014
    • TABLE 19: GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT FUNGAL HAI, THROUGH 2020 ($ MILLIONS)
    • TABLE 20: GLOBAL MARKET FOR HAI PHARMACEUTICALS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 21: AMERICAS MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HAI BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 22: AMERICAS MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HAI BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 23: EMRA MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HAI BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 24: EMRA MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HAI, BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 25: ASIAN MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HAI BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 26: ASIAN MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HAI, BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 27: GLOBAL MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 28: SURVIVAL OF HOSPITAL PATHOGENS ON DRY HOSPITAL SURFACES
    • TABLE 29: ADVANTAGES/DISADVANTAGES OF COMMONLY USED DISINFECTANTS
    • TABLE 30: GLOBAL MARKET FOR DISINFECTANT PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2020 ($ MILLIONS)
    • TABLE 31: GLOBAL MARKET FOR PATIENT SKIN PREPARATION DISINFECTANTS, THROUGH 2020 ($ MILLIONS)
    • TABLE 32: GLOBAL MARKET FOR MEDICAL STERILIZATION PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2020 ($ MILLIONS)
    • TABLE 33: GLOBAL MARKET OF IN-LINE MEDICAL FILTERS USED IN CONJUNCTION WITH MEDICAL ADMINISTRATION OF SOLUTIONS, THROUGH 2020 ($ MILLIONS)
    • TABLE 34: GLOBAL MARKET FOR MEDICAL CHEMICAL STERILIZATION EQUIPMENT AND CONSUMABLES, THROUGH 2020 ($ MILLIONS)
    • TABLE 35: GLOBAL MARKET FOR MEDICAL STEAM STERILIZATION EQUIPMENT AND CONSUMABLES, THROUGH 2020 ($ MILLIONS)
    • TABLE 36: SELECTED MATERIALS THAT RESPOND WELL TO STEAM STERILIZATION
    • TABLE 37: GLOBAL MARKET FOR RADIATION STERILIZATION PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 38: MICROBES INACTIVATED BY GAMMA IRRADIATION AND THE AMOUNT OF NECESSARY KGY
    • TABLE 39: MEDICAL GRADE POLYMERS CAPABLE OF TOLERATING GAMMA RADIATION (KGY)
    • TABLE 40: GLOBAL MARKET FOR ENVIRONMENTAL PRODUCTS/ EQUIPMENT TO CONTROL HAI, BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 41: AMERICAS MARKET FOR ENVIRONMENTAL PRODUCTS/ EQUIPMENT TO CONTROL HAI BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 42: AMERICAS MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS BY PRODUCT TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 43: EMRA MARKET FOR ENVIRONMENTAL PRODUCTS/ EQUIPMENT TO CONTROL HAI BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 44: EMRA MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2020 ($ MILLIONS)
    • TABLE 45: ASIAN MARKET FOR ENVIRONMENTAL PRODUCTS/ EQUIPMENT TO CONTROL HAI, THROUGH 2020 ($ MILLIONS)
    • TABLE 46: ASIAN MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2020 ($ MILLIONS)
    • TABLE 47: GLOBAL MARKET FOR MEDICAL DEVICES THAT ARE DESIGNED TO MINIMIZE HAI, THROUGH 2020 ($ MILLIONS)
    • TABLE 48: GLOBAL MARKET FOR CATHETERS WITH ANTIMICROBIAL PROPERTIES BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 49: KEY MANUFACTURERS OF ANTIBIOTIC-COATED CATHETERS BY NAME, LOCATION AND PRODUCTS, 2014
    • TABLE 50: GLOBAL HAI CATHETER MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 51: GLOBAL MARKET FOR PATIENT VENTILATION PRODUCTS, THROUGH 2020 ($ MILLIONS)
    • TABLE 52: GLOBAL MARKET FOR NONINVASIVE VENTILATION SYSTEMS FOR USE WITH HAI-INFECTED PATIENTS, THROUGH 2020 ($ MILLIONS)
    • TABLE 53: GLOBAL MARKET FOR COATED ENDOTRACHEAL TUBES DESIGNED TO MINIMIZE VAP, THROUGH 2020 ($ MILLIONS)
    • TABLE 54: GLOBAL STERILE IV FILTER MARKET, THROUGH 2020 ($ MILLIONS)
    • TABLE 55: GLOBAL MARKET FOR PATIENT INFECTION CONTROL DEVICES BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 56: AMERICAS MARKET FOR INFECTION CONTROL DEVICES DESIGNED TO MINIMIZE HAI, BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 57: AMERICAS MARKET FOR CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2020 ($ MILLIONS)
    • TABLE 58: EMRA MARKET FOR INFECTION CONTROL DEVICES DESIGNED TO MINIMIZE HAI, BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 59: EMRA MARKET FOR CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2020 ($ MILLIONS)
    • TABLE 60: ASIAN MARKET FOR INFECTION CONTROL DEVICES DESIGNED TO MINIMIZE HAI BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 61: ASIAN MARKET FOR CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2020 ($ MILLIONS)
    • TABLE 62: HAI PHARMACEUTICAL PRODUCT PIPELINE
    • TABLE 63: SELECTED HAI-RELATED PHARMACEUTICAL PATENT EXPIRATIONS, 2004-2024
    • TABLE 64: NUMBER OF SELECTED PATENTS BY TYPE, JANUARY 2010 THROUGH FEBRUARY 2015
    • TABLE 65: PHARMACEUTICAL PATENTS BY DATE OF ISSUE, JANUARY 2010 THROUGH MARCH 2015
    • TABLE 66: ENVIRONMENTAL PATENTS* BY DATE OF ISSUE, JANUARY 2010 THROUGH MARCH 2015
    • TABLE 67: MEDICAL DEVICE PATENTS BY DATE OF ISSUE, JANUARY 2010 THROUGH MARCH 2015
    • TABLE 68: NUMBER OF PATENTS BY MANUFACTURER, JANUARY 2010 THROUGH FEBRUARY 2015
    • TABLE 69: PATENTS ON BACTERIAL PHARMACEUTICALS, SEPTEMBER 2010 THROUGH MARCH 2015
    • TABLE 70: PATENTS ON FUNGAL PHARMACEUTICALS, SEPTEMBER 2010 THROUGH FEBRUARY 2015
    • TABLE 71: PATENTS ON VIRAL PHARMACEUTICALS, JANUARY 2011 THROUGH MARCH 2015
    • TABLE 72: PATENTS ON AIR FILTRATION, FEB 2011-MARCH 2013
    • TABLE 73: PATENTS ON WATER TREATMENT, SEPTEMBER 2010 TO MARCH 2014
    • TABLE 74: PATENTS ON SOLID WASTE TREATMENT, APRIL 2011 THROUGH DECEMBER 2014
    • TABLE 75: PATENTS ON SURFACE DISINFECTANTS, JANUARY 2010 TO DECEMBER 2014
    • TABLE 76: PATENTS ON PATIENT DISINFECTANTS, DECEMBER 2010 TO APRIL 2013
    • TABLE 77: PATENTS ON CATHETERS, JULY 2010 TO FEBRUARY 2015
    • TABLE 78: PATENTS ON ANTIMICROBIAL COATINGS, AUGUST 2010 THROUGH JANUARY 2015
    • TABLE 79: ABBOTT HAI PRODUCTS
    • TABLE 80: ABBVIE HAI PRODUCTS
    • TABLE 81: ACTAVIS HAI PRODUCTS
    • TABLE 82: ASTELLAS HAI PRODUCTS
    • TABLE 83: ASTRAZENECA HAI PRODUCTS
    • TABLE 84: B. BRAUN HAI PRODUCTS
    • TABLE 85: BASILEA HAI PRODUCTS
    • TABLE 86: BAYER HAI PRODUCTS
    • TABLE 87: BRISTOL MYERS SQUIBB HAI PRODUCTS
    • TABLE 88: GILEAD SCIENCES HAI PRODUCTS
    • TABLE 89: GLAXOSMITHKLINE HAI PRODUCTS
    • TABLE 90: JANSSEN THERAPEUTICS HAI PRODUCTS
    • TABLE 91: JOHNSON & JOHNSON HAI PRODUCTS
    • TABLE 92: MERCK HAI PRODUCTS
    • TABLE 93: NOVARTIS HAI PRODUCTS
    • TABLE 94: PFIZER HAI PRODUCTS
    • TABLE 95: ROCHE HAI PHARMACEUTICAL PRODUCTS
    • TABLE 96: SHIRE HAI PHARMACEUTICAL PRODUCTS
    • TABLE 97: SUN PHARMA HAI PHARMACEUTICAL PRODUCTS
    • TABLE 98: THE MEDICINE COMPANY HAI PHARMACEUTICAL PRODUCTS
    • TABLE 99: THERAVANCE HAI PRODUCTS
    • TABLE 100: TOYAMA CHEMICAL HAI PRODUCTS
    • TABLE 101: VENUS REMEDIES HAI PRODUCTS

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL MARKET SHARES OF HAI TREATMENTS BY GEOGRAPHICAL AREA, 2015 AND 2020 (%)
    • FIGURE 1: OCCURRENCE OF HAI IN U.S. HOSPITALS BY TYPE, 2011 (%)
    • FIGURE 2: GLOBAL MARKET SHARES OF HEPATITIS, INFLUENZA AND PNEUMONIA PHARMACEUTICALS TO TREAT HAI BY COMPANY, 2014 (%)
    • FIGURE 3: GLOBAL MARKET SHARE FOR HAI VIRAL PHARMACEUTICALS, BY DISEASE TYPE, 2014 (%)
    • FIGURE 4: GLOBAL MARKET SHARES OF HAI BACTERIAL PHARMACEUTICALS BY COMPANY, 2014 (%)
    • FIGURE 5: GLOBAL MARKET SHARES OF PHARMACEUTICALS TO TREAT FUNGAL HAI, BY COMPANY, 2014 (%)
    • FIGURE 6: AMERICAS HAI PHARMACEUTICAL MARKET SHARES, BY DISEASE TYPE, 2015 AND 2020 (%)
    • FIGURE 7: EMRA HAI PHARMACEUTICAL MARKET SHARES BY DISEASE TYPE, 2015 AND 2020 (%)
    • FIGURE 8: ASIAN HAI PHARMACEUTICAL MARKET SHARES BY DISEASE TYPE, 2015 AND 2020 (%)
    • FIGURE 9: MAJOR NOSOCOMIAL INFECTIONS IN U.S. ICU BY TYPE AND PERCENT (%)
    • FIGURE 10: PROJECTED HAI CATHETER MARKET SHARES BY TYPE, 2015 AND 2020 (%)
    • FIGURE 11: PROJECTED GLOBAL HAI CATHETER MARKET SHARES BY REGION, 2015 AND 2020 (%)
    • FIGURE 12: GLOBAL HAI PATIENT INFECTION CONTROL DEVICES MARKET SHARES BY REGION, 2015 AND 2020 (%)
    • FIGURE 13: MARKET SHARE BY TYPE OF PHARMACEUTICAL COMPOUND IN DEVELOPMENT, 2014 (%)
Back to Top